9-ING-41
| Catalog Number | Pack Size | List Price* | Quantity | |
|---|---|---|---|---|
| HY-113914-5MG | 5 mg | 181,00 | Add | |
| HY-113914-1ML | 10mM/1mL | 198,00 | Add | |
| HY-113914-10MG | 10 mg | 292,00 | Add | |
| HY-113914-25MG | 25 mg | 599,00 | Add | |
| HY-113914-50MG | 50 mg | 1'059,00 | Add | |
| HY-113914-100MG | 100 mg | 1'825,00 | Add | |
| HY-113914-S-1ST | Sample | Inquire |
* CHF, excl. 8.1% VAT and shipping costs
Product Description
Best price guarantee – we offer you the lowest price in Switzerland. Please contact us for a quote if needed.
9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents[1][2][3][4].
| Category | Inhibitor |
| Supplier | MedChem Express |
| Regulatory Status | RUO |
| Research Field | Cancer, Apoptosis,Autophagy,PI3K/Akt/mTOR,Stem Cell/Wnt |
| Format | Solubility: DMSO : 50 mg/mL (ultrasonic) |
| Grade | Clinical information: Phase 2 |
| Purity | 98.83% |
| Molecular Formula | C22H13FN2O5 |
| Molecular Weight | 404.35 |
| CAS-Number | 1034895-42-5 |
| Storage Conditions | -20°C, 3 years; 4°C, 2 years (Powder) |
| Tech. Data Sheet | View datasheet |
| Link To Supplier | http://www.medchemexpress.com |
| Shipping Details | Room Temperature |
| Material Safety Data Sheet | Download PDF |
